Transcept axes workers after FDA rejection; Forest expands board; Should people who reject vaccines be sanctioned?;

@FierceBiotech: Roche gearing up to seek approvals of breast cancer treatment. News | Follow @FierceBiotech

@JohnCFierce: The "sword of Damocles" is dangling over AstraZeneca this week. Item | Follow @JohnCFierce

> Transcept Pharmaceuticals said late last week that it would cut almost half of its workforce in the wake of the FDA's rejection of its sleep drug Intermezzo. Article

> Forest Laboratories is laying plans to expand its board to 10 members as CEO Howard Solomon fights off an assault by Carl Icahn. Story

> Forest Labs says that its depression drug levomilnacipran performed well in a late-stage study, showing a statistically significant improvement among adults enrolled in the trial. The news follows Forest's announcement in January that the drug failed a key study. Two more late-stage studies will report data in the coming year. Report

> VirxSys says it has taken another step toward developing a vaccine for HIV. We are well on the path to a functional cure, at least in monkeys," says  Laurent Humeau, VirxSys vice president of  research and development. Piece

> Cyclacel and Daiichi Sankyo have restructured their deal on sapacitabine, with the Japanese company waiving "a termination right it possessed under a provision of the license agreement that required the company to obtain regulatory approval to sell sapacitabine in at least one country by September, 2011." Release

Pharma News

@FiercePharma: U.K. workers dispute Novartis severance pay. Story | Follow @FiercePharma

> Lupin said to weigh scale of Indian pharma unit. Article

> Valeant aims for top of dermatology, CEO says. Article

Biotech IT News

> Bracket buys ePRO provider arrowhead. News

> Medidata faces market hurdles, Goldman says. More

> Knome aids in Parkinson's gene discovery. Item

> CRO Icon scoops up eClinical firm Firecrest. Story

> Accelrys integrates MIT tech into updated lab software. Article

> NCI taps start-up GNS's supercomputing tech for lung cancer analysis. News

Medical Device News

> Medtronic, Stryker sued for causing woman's injuries. More

> AngioDynamics mulls move of laser unit. Item

> Medtronic invests in PowerVision. Story

> J&J unit enrolls first patient in SMART-AF study. News

> Transcend Medical boosts Series B to $51M. Article

And Finally... Harvard's David Ropeik is encouraging new measures that would punish people who reject vaccinations. Column

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.